eHealth Named to 2025 Fortune Best Workplaces in Texas by Fortune Media and Great Place To Work
AUSTIN, Texas, June 12, 2025 /PRNewswire/ -- eHealth, Inc. (Nasdaq: EHTH) (eHealth.com), a leading online private health insurance marketplace, has been named as one of this year's Best Workplaces in Texas by Great Place To Work and Fortune magazine. eHealth is proud to be named to this prestigious list, coming in at No. 25. To be selected, eHealth surpassed rigorous benchmarks and has established itself as one of the best workplaces in Texas.
To determine the Fortune Best Workplaces in Texas™ List, Great Place To Work surveyed nearly 116,000 employees at eligible companies via its proprietary platform. Companies were ranked based on their ability to offer consistently positive experiences, building trust with leaders, colleagues, and the overall organization.
"While we're proudly headquartered in Austin, our workplace excellence spans nationwide through our remote-first approach," says Jana Brown, eHealth's Chief Human Resources Officer. "This recognition places us among an elite group of companies that excel in the foundational elements that drive true workplace excellence. Our team members across the country embody our values daily, proving that when you prioritize people and create intentional connection, exceptional results follow—regardless of where the work gets done."
The Best Workplaces in Texas list is highly competitive. Survey responses reflect a comprehensive picture of the workplace experience. Honorees were rewarded based on their ability to deliver positive outcomes for employees regardless of role or status within the organization.
To be eligible for the list, companies must be Great Place To Work Certified™, have at least 10 U.S. employees, and be headquartered in Texas.
"Congratulations to the Fortune Best Workplaces in Texas," says Michael C. Bush, CEO at Great Place To Work. "These companies prove that prioritizing people leads to better performance, and that leaders who invest in their people are rewarded with more sustainable and profitable businesses."
About eHealth (NASDAQ: EHTH) We're Matchmakers. For over 25 years, eHealth has helped millions of Americans find the healthcare coverage that fits their needs at a price they can afford. Consumers can visit our health insurance marketplace at ehealth.com, or call us to speak with a licensed insurance agent at 1-833-964-1202. As a leading independent licensed insurance agency and advisor, eHealth offers access to over 180 health insurers, including national and regional companies.
For more information, visit ehealth.com or follow us on LinkedIn, Facebook, Instagram, and X. Open positions can be found on our career page.
eHealth media inquiries: pr@ehealth.com
About the Fortune Best Workplaces in Texas Great Place To Work selected the 2025 Fortune Best Workplaces in Texas by surveying 1.3 million employees in the U.S., representing companies that collectively employ more than 8.4 million U.S. workers. Of those responses, nearly 116,000 were received from employees at companies that were eligible for the 2025 Fortune Best Workplaces in Texas List, and these rankings are based on their feedback. To be eligible, companies must be Great Place To Work Certified™, have at least 10 U.S. employees, and be headquartered in Texas. Read the full methodology.
To get on this list next year, start here.
About Great Place to Work As the global authority on workplace culture, Great Place To Work brings more than three decades of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model™ help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified or receiving recognition on its coveted Best Workplaces™ lists.
Follow Great Place To Work on LinkedIn, Twitter, and Instagram or visit greatplacetowork.com and sign up for the newsletter to learn more.
About Fortune Fortune upholds a legacy of award-winning writing and trusted reporting for executives who want to make business better. Independently owned, with a global perspective and digital agility, Fortune tells the stories of a new generation of innovators, builders, and risk-takers. Online and in print, Fortune measures corporate performance through rigorous benchmarks and holds companies accountable. Fortune creates communities by convening true thought leaders and iconoclasts — those who shape industry, commerce and society — through powerful and prestigious lists, events, and conferences, such as the iconic Fortune 500, the CEO Initiative and Most Powerful Women. For more information, visit fortune.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ehealth-named-to-2025-fortune-best-workplaces-in-texas-by-fortune-media-and-great-place-to-work-302480007.html
SOURCE eHealth, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
IBM, Google Emerge As Top Investors In Quantum Computing With Most Patents Issued In 2025: 'Only Two Companies Seriously Investing,' Says Martin Shkreli
Many big tech companies, including startups, are foraying into the emerging field of quantum computing. Out of the 300 quantum computing patents issued in 2025, two companies have received the most. What Happened: International Business Machines Corp. and Alphabet Inc.'s (NASDAQ:GOOGL) Google appear to have made significant investments in the quantum computing space on a year-to-date basis. According to the data shared by Martin Shkreli, there was a steep drop-off in issued patents after IBM and Google, suggesting that other companies are either smaller players or not prioritizing quantum computing as heavily. IonQ Inc., D-Wave Quantum Inc., PsiQuantum, Quantinuum, and Intel Corp., followed the first two firms. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Furthermore, he highlighted that Wells Fargo & Co. (NYSE:WFC), Bank of America Corp. (NYSE:BAC), and JPMorgan Chase & Co. (NYSE:JPM) also hold quantum patents, which he describes as 'big company spend.' Large corporations often invest in emerging technologies like quantum computing to hedge against future disruptions, even if they're not leading the field. Shkreli also notes that companies like Cisco Systems Inc. (NASDAQ:CSCO) are working on Quantum Key Distribution (QKD) and quantum networking patents. QKD uses quantum mechanics to secure communications, offering theoretically unbreakable encryption. Lastly, Shkreli suggests that Microsoft Corp.'s patent output doesn't match its spending or public statements, implying they may be focusing more on development or partnerships rather than patenting their work. Why It Matters: The evolving quantum computing space relies on qubits, which, unlike classical bits in traditional computers, can superpose and entangle 0 and 1 to solve complex problems. While still in the development stage, many publicly listed firms are involved in their research and development. Here's a list of a few companies and an exchange-traded fund that tracks such YTD Performance One Year Performance International Business Machines Corp. (NYSE:IBM) 28.00% 66.58% Alphabet Inc. (NASDAQ:GOOG) -6.21% -0.43% Intel Corp. (NASDAQ:INTC) 2.27% -32.77% Cisco Systems Inc. (NASDAQ:CSCO) 8.61% 40.71% Microsoft Corp. (NASDAQ:MSFT) 12.91% 7.16% IonQ Inc (NYSE:IONQ) -7.89% 399.37% D-Wave Quantum Inc (NYSE:QBTS) 72.01% 1325.00% Rigetti Computing Inc (NASDAQ:RGTI) -37.40% 1127.45% Quantum Computing Inc (NASDAQ:QUBT) 1.12% 2864.06% Defiance Quantum ETF (NASDAQ:QTUM) 8.24% 38.92% The SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, fell on Wednesday. The SPY was down 0.29% at $601.36, while the QQQ declined 0.34% to $532.41, according to Benzinga Pro data. The futures of the S&P 500, Dow Jones, and Nasdaq 100 indices fell on Thursday. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: JHVEPhoto / Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article IBM, Google Emerge As Top Investors In Quantum Computing With Most Patents Issued In 2025: 'Only Two Companies Seriously Investing,' Says Martin Shkreli originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib REDWOOD CITY, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea' or the 'Company') (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced updated preliminary clinical data from the ongoing Phase I COVALENT-103 trial of BMF-500 in adults with relapsed or refractory ('R/R') acute leukemia ('AL'). The results will be presented in a poster presentation at the European Hematology Association ('EHA') 2025 Congress in Milan, Italy. The presentation by Dr. Farhad Ravandi of The University of Texas MD Anderson Cancer Center will highlight emerging safety, pharmacokinetics/pharmacodynamics, and early clinical activity data for BMF-500, a highly selective covalent FMS-like tyrosine kinase 3 ('FLT3') inhibitor, in heavily pretreated patients with R/R AL. Key Results from the EHA 2025 Poster Presentation27 patients were enrolled across two study arms, Arm A (no CYP3A4 inhibitor; n=10) and Arm B (CYP3A4 inhibitor; n=17). All patients had R/R AL, with a median of 4 prior lines of therapy. 18 of the 27 patients were FLT3 mutations ('FLT3m') while the other 9 patients had FLT3 wild-type AL. Frequent co-mutations included WT1, TP53, IDH1/2, and NRAS. All 18 FLT3m patients had failed gilteritinib in the R/R setting and 9 of the 18 had received at least two FLT3 inhibitors prior to study entry. 26 of 27 (96%) enrolled patients had also received and failed the BCL2 inhibitor venetoclax. Key findings include: Clinical Activity Observed: 9 of 11 efficacy-evaluable FLT3m patients, defined as all patients enrolled who received at least one dose and had at least one disease assessment, showed bone marrow (BM) blast reduction; 5 of 11 achieved >50% BM blast reduction. 1 FLT3m patient achieved complete remission with incomplete hematologic recovery (CRi), sustained for 6 cycles. 1 FLT3m patient achieved morphologic leukemia-free state (MLFS); response is ongoing. 1 FLT3m patient met all criteria for partial response (PR) except platelet recovery; categorized as near PR. 2 of 4 efficacy-evaluable FLT3 wild-type patients achieved durable disease control ≥120 days, with treatment ongoing for one patient. Additional clinical improvements include reductions in peripheral blasts, transfusion dependency, and frequency of hydroxyurea use. Pharmacokinetics/Pharmacodynamics: FLT3 inhibition correlated with BMF-500 systemic exposures. Bone marrow and plasma concentrations of BMF-500 and its metabolites were comparable, suggesting good compartmental penetration. Survival: Median overall survival (mOS) among all treated FLT3m patients (n=18) was 3.8 months (Arm A) and 3.5 months (Arm B) during dose escalation. For the efficacy-evaluable FLT3m patients (n=12), the mOS for Arms A and B was 3.8 and 3.6 months, respectively during dose escalation. These survival durations compare favorably to historical mOS of 2.1 months in patients with R/R FLT3m acute myeloid leukemia ('AML') post-failure with both gilteritinib and venetoclax. 1 Ongoing Dose Escalation: Dose escalation continues at 200 mg BID (Arm A) and 75 mg BID (Arm B). Based on observed activity and tolerability, further evaluation is underway to determine optimal biologic dose ('OBD') and recommended Phase II dose ('RP2D'). Safety and Tolerability BMF-500 was generally well-tolerated across dose levels. No dose-limiting toxicities (DLTs), QT prolongation, or discontinuations due to treatment-related adverse events were reported. Escalation is ongoing without safety restrictions. 'The updated COVALENT-103 results continue to support the potential of BMF-500 as a selective, covalent FLT3 inhibitor,' said Mick Hitchcock, Ph.D., Interim Chief Executive Officer of Biomea Fusion. 'We are encouraged by the depth of bone marrow responses, the achievement of MLFS and CRi, and the early survival benefit in heavily pretreated patients with FLT3 mutations who had progressed following prior FLT3 inhibitor therapy. These data speak to BMF-500's potential to meaningfully improve outcomes in a high-risk AML population with no currently available treatment options.' Following completion of the COVALENT-103 dose escalation phase in R/R AL patients with FLT3m, Biomea plans to conclude its internal development of BMF-500 in oncology and is actively exploring strategic partnerships to advance the program. Poster Presentation Details Date/Time: Saturday, June 14 (18:30-19:30 CEST) Title: Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the COVALENT-103 Study (NCT05918692) Poster Number: PS1520 Presenter: Farhad Ravandi, M.D., University of Texas MD Anderson Cancer Center About COVALENT-103 COVALENT-103 is a multicenter, open-label, non-randomized trial seeking to evaluate the safety and efficacy of BMF-500, a twice daily oral treatment, in adult patients with R/R AL with FLT3 wild-type or FLT3m. The Phase I COVALENT-103 study aims to evaluate the safety and tolerability of BMF-500, determine the optimal biologic dose and recommended Phase II dose, and identify initial efficacy signals. Additional information about the Phase I clinical trial of BMF-500 can be found at using the identifier, NCT05918692. About BMF-500 BMF-500 is an investigational, orally bioavailable, covalent small molecule inhibitor of FLT3, discovered in-house using Biomea's proprietary FUSION™ System. Designed to be highly potent and selective, BMF-500 has demonstrated encouraging potential in extensive preclinical studies. Its kinase inhibitory profile indicates strong target selectivity, which may translate to a reduced risk of off-target effects. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both designed to significantly improve the lives of patients with diabetes, obesity, and other metabolic diseases. We aim to cure. Visit us at and follow us on LinkedIn, X, and Facebook. Forward-Looking Statements Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-500, the potential of BMF-500 as a treatment for patients with FLT3m R/R AL, our research, development, partnership and regulatory plans, and the timing of such events may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that preliminary or interim results of preclinical studies or clinical trials may not be predictive of future or final results in connection with future clinical trials and the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea's business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (SEC), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Reference: 1. Corley et al. (P1798) HemaSphere 2024;8(S1), 3339-3340. Contact: Meichiel Jennifer Weiss Sr. Director, Investor Relations and Corporate DevelopmentIR@
Yahoo
35 minutes ago
- Yahoo
Elite Capital & Co. Limited Moves to 1 Cornhill After 12 Years at 33 St. James Square Amid Financial Sector Expansion
LONDON, June 13, 2025 (GLOBE NEWSWIRE) -- Mr. George Matharu, President and CEO of Elite Capital & Co. Limited, announced today that Elite Capital & Co. has relocated its headquarters from 33 St. James Square to the iconic 1 Cornhill, a landmark building in London's financial district.'This move marks a pivotal moment in our growth. The expansion of our operations in the financial sector, coupled with the integration of NextGen Industrial Development Fund's team into Elite Capital & Co. Limited, demanded exceptional scalability. 1 Cornhill provides the ideal environment to accommodate our ambitious vision and reinforce our leadership in global finance,' Mr. George Matharu Capital & Co. Limited is a Financial Management company that provides project-related services, including Management, Consultancy, and Funding, particularly for large infrastructure and mega commercial Capital & Co. Limited offers a wealth of experience in Banking and Financial transactions and has a range of specialized advisory services for private clients, medium and large corporations as well as governments. It is also the exclusive manager of the Government Future Financing 2030 Program® and NextGen Industrial Development Fund™.Dr. Faisal Khazaal, Chairman of Elite Capital & Co., added, 'Leaving 33 St. James Square is bittersweet, it's where we built a legacy, sealing landmark deals that shaped our identity. Yet, 1 Cornhill represents a bold new chapter, mirroring Elite Capital's stature not just in London, but as a global force in finance.'NextGen Industrial Development Fund redefines industrial financing by replacing debt with equity partnerships, empowering entrepreneurs to build factories without the burden of collateral or loan repayments. Targeting first-time industrialists and global firms expanding into MENA, NextGen provides end-to-end support, from land acquisition and infrastructure construction to cross-border financial solutions, ensuring projects thrive from day a fund managed by Elite Capital & Co. Limited, NextGen's innovative model aligns perfectly with Elite Capital's vision for scalable, risk-shared growth. Together, they bridge the gap between visionary ideas and tangible industrial success, transforming the financial landscape for large-scale projects George Matharu concluded his statement by saying: 'Our new home is more than an address; it's a testament to our clients, partners, and team who drive our success. We invite you to visit us at 1 Cornhill as we write the next era of excellence.' Contact Details – Elite Capital & Co. Limited1 Cornhill, City of LondonEngland, EC3V 3ND Telephone: +44 (0) 203 709 5060SWIFT Code: ELCTGB21LEI Code: 254900NNN237BBHG7S26 Website: A photo accompanying this announcement is available at
